Abstract
RNA molecules perform diverse regulatory functions in natural biological systems, and numerous synthetic RNA-based control devices that integrate sensing and gene-regulatory functions have been demonstrated, predominantly in bacteria and yeast. Despite potential advantages of RNA-based genetic control strategies in clinical applications, there has been limited success in extending engineered RNA devices to mammalian gene-expression control and no example of their application to functional response regulation in mammalian systems. Here we describe a synthetic RNA-based regulatory system and its application in advancing cellular therapies by linking rationally designed, drug-responsive, ribozyme-based regulatory devices to growth cytokine targets to control mouse and primary human T-cell proliferation. We further demonstrate the ability of our synthetic controllers to effectively modulate T-cell growth rate in response to drug input in vivo. Our RNA-based regulatory system exhibits unique properties critical for translation to therapeutic applications, including adaptability to diverse ligand inputs and regulatory targets, tunable regulatory stringency, and rapid response to input availability. By providing tight gene-expression control with customizable ligand inputs, RNA-based regulatory systems can greatly improve cellular therapies and advance broad applications in health and medicine.
MeSH Terms
Animals
Cell Line
Cell Proliferation
Cell Survival
Gene Expression Regulation
Genetic Engineering/methods
Humans
Interleukin-15/metabolism
Mammals/metabolism
Mice
Pharmaceutical Preparations
RNA, Catalytic/metabolism
T-Lymphocytes/cytology
Time Factors
Chemicals
Interleukin-15
Pharmaceutical Preparations
RNA, Catalytic
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Chen Yvonne Y
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Jensen Michael C
Smolke Christina D
References (30)
30 references, click to expand
-
Prediction of RNA secondary structure by free energy minimization.
Curr Opin Struct Biol. 2006 Jun;16(3):270-8
PMID: 16713706
-
Design principles for riboswitch function.
PLoS Comput Biol. 2009 Apr;5(4):e1000363
PMID: 19381267
-
Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.
Immunity. 2001 Feb;14(2):105-10
PMID: 11239443
-
Long term culture of tumour-specific cytotoxic T cells.
Nature. 1977 Jul 14;268(5616):154-6
PMID: 145543
-
Adoptive immunotherapy for cancer: building on success.
Nat Rev Immunol. 2006 May;6(5):383-93
PMID: 16622476
-
Pharmacologically regulated in vivo selection in a large animal.
Blood. 2002 Sep 15;100(6):2026-31
PMID: 12200362
-
High-resolution molecular discrimination by RNA.
Science. 1994 Mar 11;263(5152):1425-9
PMID: 7510417
-
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science. 2006 Oct 6;314(5796):126-9
PMID: 16946036
-
Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia.
Immunol Rev. 1997 Jun;157:223-30
PMID: 9255633
-
Higher-order cellular information processing with synthetic RNA devices.
Science. 2008 Oct 17;322(5900):456-60
PMID: 18927397
-
Engineered riboregulators enable post-transcriptional control of gene expression.
Nat Biotechnol. 2004 Jul;22(7):841-7
PMID: 15208640
-
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Cancer Res. 2004 Dec 15;64(24):9160-6
PMID: 15604287
-
Frameworks for programming biological function through RNA parts and devices.
Chem Biol. 2009 Mar 27;16(3):298-310
PMID: 19318211
-
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
J Immunol. 2004 Dec 15;173(12):7125-30
PMID: 15585832
-
Improving T cell therapy for cancer.
Annu Rev Immunol. 2007;25:243-65
PMID: 17129181
-
Complex riboswitches.
Science. 2008 Mar 28;319(5871):1795-7
PMID: 18369140
-
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
PMID: 12427970
-
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
J Clin Invest. 2008 Jan;118(1):294-305
PMID: 18060041
-
Principles of adoptive T cell cancer therapy.
J Clin Invest. 2007 May;117(5):1204-12
PMID: 17476350
-
RNA synthetic biology.
Nat Biotechnol. 2006 May;24(5):545-54
PMID: 16680139
-
Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.
J Immunol. 2005 Dec 1;175(11):7226-34
PMID: 16301627
-
The RNAi revolution.
Nature. 2004 Jul 8;430(6996):161-4
PMID: 15241403
-
A tetracycline-binding RNA aptamer.
Bioorg Med Chem. 2001 Oct;9(10):2549-56
PMID: 11557342
-
A modular and extensible RNA-based gene-regulatory platform for engineering cellular function.
Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14283-8
PMID: 17709748
-
In vitro selection of functional nucleic acids.
Annu Rev Biochem. 1999;68:611-47
PMID: 10872462
-
A proliferation switch for genetically modified cells.
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3076-81
PMID: 9096348
-
The catalytic diversity of RNAs.
Nat Rev Mol Cell Biol. 2005 May;6(5):399-412
PMID: 15956979
-
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
N Engl J Med. 1995 Oct 19;333(16):1038-44
PMID: 7675046
-
Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8705-9
PMID: 7568001
-
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
J Clin Oncol. 2006 Nov 1;24(31):5060-9
PMID: 17075125